Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | REGN4336 |
Synonyms | |
Therapy Description |
REGN4336 is a a bispecific antibody that targets prostate-specific membrane antigen (PSMA) expressed on tumor cells and the CD3 antigen expressed on T-lymphocytes, potentially leading to activation and recruitment of cytotoxic T-lymphocytes (CTL) to tumor cells expressing PSMA and CTL-mediated tumor cell killing (NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
REGN4336 | REGN-4336|REGN 4336 | CD3 Antibody 97 PSMA Antibody 20 | REGN4336 is a a bispecific antibody that targets prostate-specific membrane antigen (PSMA) expressed on tumor cells and the CD3 antigen expressed on T-lymphocytes, potentially leading to activation and recruitment of cytotoxic T-lymphocytes (CTL) to tumor cells expressing PSMA and CTL-mediated tumor cell killing (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05125016 | Phase Ib/II | REGN4336 Cemiplimab + REGN4336 | REGN4336 (a PSMAXCD3 Bispecific Antibody) Administered Alone or in Combination With Cemiplimab in Adult Male Patients With Metastatic Castration-Resistant Prostate Cancer | Recruiting | USA | 0 |